Shelley Hay

3.3k total citations · 1 hit paper
40 papers, 2.7k citations indexed

About

Shelley Hay is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shelley Hay has authored 40 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 16 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Shelley Hay's work include Bone health and treatments (13 papers), Cell death mechanisms and regulation (11 papers) and Bone Metabolism and Diseases (9 papers). Shelley Hay is often cited by papers focused on Bone health and treatments (13 papers), Cell death mechanisms and regulation (11 papers) and Bone Metabolism and Diseases (9 papers). Shelley Hay collaborates with scholars based in Australia, United States and Saudi Arabia. Shelley Hay's co-authors include Stephen E. Graves, Andrew C.W. Zannettino, Stan Gronthos, Andreas Evdokiou, David M. Findlay, David R. Haynes, Songtao Shi, Paul J. Simmons, Gerald J. Atkins and Stelios Bouralexis and has published in prestigious journals such as Biomaterials, Cancer Research and Journal of Bone and Joint Surgery.

In The Last Decade

Shelley Hay

40 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow

2003 813 citations Andrew C.W. Zannettino, Shelley Hay et al. profile →

Peers

Countries citing papers authored by Shelley Hay

Since Specialization

Citations

This map shows the geographic impact of Shelley Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelley Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelley Hay more than expected).

Fields of papers citing papers by Shelley Hay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shelley Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelley Hay. The network helps show where Shelley Hay may publish in the future.

Co-authorship network of co-authors of Shelley Hay

This figure shows the co-authorship network connecting the top 25 collaborators of Shelley Hay. A scholar is included among the top collaborators of Shelley Hay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelley Hay. Shelley Hay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Titanium wire implants with nanotube arrays: A study model for localized cancer treatment 2016 ·Biomaterials ·(unknown), (unknown), Karan Gulati, Irene Zinonos, Ye Wang, (unknown), Shelley Hay, Dušan Lošić, Andreas Evdokiou	39
2	Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer 2016 ·Cancer Letters ·(unknown), Mark DeNichilo, Vasilios Panagopoulos, Irene Zinonos, Vasilios Liapis, Shelley Hay, Wendy V. Ingman, Vladimir Ponomarev, Gerald J. Atkins, David M. Findlay, Andrew C.W. Zannettino, Andreas Evdokiou	22
3	Uncovering a new role for peroxidase enzymes as drivers of angiogenesis 2015 ·The International Journal of Biochemistry & Cell Biology ·Vasilios Panagopoulos, Irene Zinonos, Damien A. Leach, Shelley Hay, Vasilios Liapis, (unknown), Wendy V. Ingman, Mark DeNichilo, Andreas Evdokiou	28
4	Systematic in vitro nanotoxicity study on anodic alumina nanotubes with engineered aspect ratio: Understanding nanotoxicity by a nanomaterial model 2015 ·Biomaterials ·Ye Wang, Gagandeep Kaur, (unknown), Vasilios Liapis, Shelley Hay, Abel Santos, Dušan Lošić, Andreas Evdokiou	40
5	Peroxidase Enzymes Regulate Collagen Biosynthesis and Matrix Mineralization by Cultured Human Osteoblasts 2015 ·Calcified Tissue International ·Mark DeNichilo, (unknown), Vasilios Panagopoulos, Vasilios Liapis, (unknown), Irene Zinonos, Shelley Hay, Gerald J. Atkins, David M. Findlay, Andreas Evdokiou	15
6	Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer 2014 ·International Journal of Oncology ·Irene Zinonos, Ke-Wang Luo, Agatha Labrinidis, Vasilios Liapis, Shelley Hay, Vasilios Panagopoulos, Mark DeNichilo, Chun‐Hay Ko, Grace Gar‐Lee Yue, Clara Bik‐San Lau, Wendy V. Ingman, Vladimir Ponomarev, Gerald J. Atkins, David M. Findlay, Andrew C.W. Zannettino, Andreas Evdokiou	19
7	Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma 2014 ·Cancer Letters ·Vasilios Liapis, Agatha Labrinidis, Irene Zinonos, Shelley Hay, Vladimir Ponomarev, Vasilios Panagopoulos, Mark DeNichilo, Wendy V. Ingman, Gerald J. Atkins, David M. Findlay, Andrew C.W. Zannettino, Andreas Evdokiou	41
8	Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer 2009 ·Molecular Cancer Therapeutics ·Irene Zinonos, Agatha Labrinidis, Michelle Lee, Vasilios Liapis, Shelley Hay, Vladimir Ponomarev, Peter Diamond, Andrew C.W. Zannettino, David M. Findlay, Andreas Evdokiou	37
9	Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in both an immunodeficient and immunocompetent animal model 2009 ·Bone ·Agatha Labrinidis, Vasilios Liapis, Shelley Hay, (unknown), Andreas Evdokiou	7
10	Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males 2008 ·Arthritis Research & Therapy ·David M. Findlay, Mellick Chehade, (unknown), Susan D. Neale, Shelley Hay, Blair Hopwood, (unknown), Peter D. O’Loughlin, Nicola L. Fazzalari	28
11	Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin 2004 ·International Journal of Oncology ·Stelios Bouralexis, Mark Clayer, Gerald J. Atkins, Agatha Labrinidis, Shelley Hay, Stephen E. Graves, David M. Findlay, Andreas Evdokiou	13
12	Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis 2003 ·Bone ·Andreas Evdokiou, Agatha Labrinidis, Stelios Bouralexis, Shelley Hay, David M. Findlay	65
13	Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism 2002 ·Journal of Endocrinology ·(unknown), (unknown), Stelios Bouralexis, Shelley Hay, Gerald J. Atkins, Andreas Evdokiou	13
14	Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis 2002 ·Bone ·Gerald J. Atkins, Stelios Bouralexis, Andreas Evdokiou, Shelley Hay, Agatha Labrinidis, Andrew C.W. Zannettino, David R. Haynes, David M. Findlay	55
15	Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis 2002 ·International Journal of Cancer ·Andreas Evdokiou, Stelios Bouralexis, Gerald J. Atkins, Fugui Chai, Shelley Hay, Mark Clayer, David M. Findlay	113
16	Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone 2001 ·Bone ·Gerald J. Atkins, Stelios Bouralexis, David R. Haynes, Stephen E. Graves, Sean M. Geary, Andreas Evdokiou, Andrew C.W. Zannettino, Shelley Hay, David M. Findlay	82
17	Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone 2001 ·International Journal of Oncology ·Andreas Evdokiou, Gerald J. Atkins, (unknown), Shelley Hay, Liza J. Raggatt, Prue Cowled, Stephen E. Graves, Mark Clayer, (unknown)	19
18	Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors 2000 ·Journal of Bone and Mineral Research ·Gerald J. Atkins, David R. Haynes, Stephen E. Graves, Andreas Evdokiou, Shelley Hay, Stelios Bouralexis, David M. Findlay	158
19	Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells 2000 ·Bone ·Shinji Kitahama, Mark A. Gibson, George Hatzinikolas, Shelley Hay, J.S. Kuliwaba, Andreas Evdokiou, Gerald J. Atkins, David M. Findlay	51
20	Regulation of bone cells by particle-activated mononuclear phagocytes 1997 ·Journal of Bone and Joint Surgery - British Volume ·David R. Haynes, Shelley Hay, Susan Rogers, Shuichi Ohta, Donald W. Howie, Stephen E. Graves	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact